Bausch + Lomb Corporation announced it will release its third-quarter financial results on Wednesday, October 28, 2026. The global eye health company scheduled a conference call and live webcast to discuss the results and provide a business update at 8:00 am ET.

Earnings call details

Investors can access all materials, including the press release and presentation slides, on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. The company has provided specific dial-in numbers and access codes for participants wishing to join the live discussion.

Replay availability

For those unable to attend the live session, a replay will be available starting shortly after the conclusion of the call. The replay service will remain accessible until November 11, 2026. Participants can access the replay using the designated passcode provided in the announcement.

About the company

Bausch + Lomb is a leading global eye health company dedicated to helping people see better to live better. The company offers a comprehensive portfolio of products, including contact lenses, prescription products, over-the-counter options, and surgical devices. Its mission focuses on innovation and improving the standard of care in eye health worldwide.

The US Food and Drug Administration issued a warning letter to Bausch + Lomb Inc, citing inadequate aseptic controls and persistent microbial contamination at its Tampa manufacturing plant.

The regulatory action stems from inspections that identified critical failures in sterile drug manufacturing processes. The FDA determined that products manufactured at the facility are adulterated due to these violations.

Regulatory Findings

The warning letter highlights specific deficiencies in the company's quality control systems. Key issues include:

• Inadequate aseptic controls during production
• Persistent microbial contamination in the manufacturing environment
• Failure to maintain required sanitary conditions for sterile drugs

These findings indicate a breakdown in the fundamental protocols necessary for producing safe, injectable or sterile pharmaceutical products.

Impact on Operations

The designation of products as adulterated carries significant regulatory weight. It implies that the items do not meet the safety and purity standards mandated by US law. The company must address these violations to resume compliant operations at the Tampa site.

The FDA has published the warning letter on its official website, making the details of the inspection findings publicly available for stakeholders and investors to review.